Archive | Clinical Trials

Melanoma-Specific Survival With Completion Dissection vs Observation for Sentinel Node Metastasis

The phase III MSLT-II trial showed that completion dissection was not associated with improved melanoma-specific overall survival vs observation in patients with sentinel node metastasis, although a benefit was observed in regional disease control.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Glembatumumab Vedotin Shows Promising Overall Response in Advanced Melanoma

Patients with refractory advanced melanoma who had received prior treatment with a checkpoint inhibitor demonstrated promising overall response rate (ORR) and duration of response (DOR) in a phase II study involving the antibody-drug conjugate (ADC) glembatumumab vedotin (GV).

Read the full story

Posted in Melanoma In The News, Clinical Trials

Pembrolizumab plus reduced-dose ipilimumab confers durable antitumor activity in advanced melanoma

CHICAGO — The combination of standard-dose pembrolizumab and low-dose ipilimumab led to robust and durable antitumor activity with a manageable safety profile in patients with advanced melanoma, according to mature data from KEYNOTE-029.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Trial of Melanoma Triplet Combo Raises Questions

Source: Targeted Oncology, June 2017 A 3-drug regimen for advanced melanoma led to objective responses in a majority of patients with advanced BRAF-mutant disease but also proved to be somewhat toxic, a small phase II study showed.1 Results showed that 22 of 42 patients (52.4%) had complete or partial responses when treated with the BRAF […]

Read the full story

Posted in Melanoma In The News, Clinical Trials

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories